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Abstract
Background: The purpose of this study was to determine whether first trimester trisomy screening (FTS)
parameters are affected by alcohol and drug use.
Methods: A routine combined FTS including measurements of maternal serum levels of free β-human chorionic
gonadotropin subunit (free β-hCG) and pregnancy-associated plasma protein A (PAPP-A) were measured at 9–11
weeks of gestation, and fetal nuchal translucency thickness (NTT) at 11–13 weeks of gestation. In total 544 women
with singleton pregnancies [71 alcohol and drug abusers, 88 smokers, 168 non-smokers delivering a small for
gestational age (SGA) child, and 217 unexposed control women] were assessed.
Results: Free β-hCG levels were higher in alcohol and drug abusing than in unexposed pregnant women [mean
1.5 vs. 1.2 multiples of medians (MoM); P = 0.013]. However, stepwise multiple linear regression analyses suggested
that smoking could explain increased free β-hCG. Additionally, we observed lower PAPP-A levels in the smoking
mothers (0.9 vs. 1.2 MoM; P = 0.045) and in those giving birth to an SGA child compared to the controls (1.1 vs.. 1.2
MoM; P < 0.001). Fetal NTT did not differ significantly between any of the groups.
Conclusions: The present study shows increased free β-hCG levels in alcohol and drug abusers, but maternal
smoking may explain the result. Maternal serum PAPP-A levels were lower in smoking than non-smoking mothers,
and in mothers delivering an SGA child. However, FTS parameters (PAPP-A, free β-hCG and NTT) seem not to be
applicable for the use as alcohol biomarkers because of their clear overlap between alcohol abusers and healthy
controls.
Keywords: First trimester screening, PAPP-A, free β-hCG, nuchal translucency, alcohol, smoking, small for gestational age
Synopsis
Higher free β-hCG levels and unaltered PAPP-A
levels were found in alcohol-abusing pregnant
mothers. Prevalent smoking among the alcohol and
drug abusing mothers may explain partly the higher
free β-hCG levels.
Background
One of the challenges for accurate detection and timely
treatment of children with fetal alcohol exposure is the
difficulty to confirm alcohol exposure during pregnancy,
because we lack a reliable biomarker of alcohol abuse
[1–3]. The use of available biomarkers of alcohol con-
sumption are hampered by a number of problems: the
time window for detection of alcohol use is not suffi-
cient, the biomarker may be insensitive or unspecific,
the use of the biomarker has not been validated, or preg-
nancy itself affects the behaviour of the biomarker [4, 5].
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A combination of several biomarkers increases accuracy,
but proper validation of such combinations has not been
performed in pregnant women [1, 6, 7].
A combined first trimester screening (FTS) test for
chromosomal abnormalities includes measurements of
pregnancy-associated plasma protein A (PAPP-A) and
free β-human chorionic gonadotropin subunit (free β-
hCG) from maternal serum, fetal nuchal translucency
thickness (NTT), and recording the mother´s age. This
combination identifies 85–95% of all fetuses with triso-
mies 21, 18 and 13, at a false positive rate of 5% [8].
PAPP-A and free β-hCG are known to be influenced
by maternal and pregnancy variables such as gestational
age, maternal weight, smoking and ethnic background
[9]. There is growing evidence that decreased PAPP-A is
associated with a delivery of a small for gestational age
(SGA) child at the end of pregnancy, even though the
systematic review and meta-analysis of Morris et al. [10]
showed that the sensitivity of PAPP-A to predict the
birth of an SGA child remains low. Previous experiments
with human placental cell lines and extraction analyses
using human placental samples demonstrated that etha-
nol exposure increased hCG production. Thus, hCG was
suggested for a candidate surrogate biomarker of pre-
natal ethanol exposure [11]. The influence of drug abuse
on first trimester screening parameters has not been pre-
viously reported. However, it seems that maternal opioid
use does not significantly affect second trimester free β-
hCG levels [12].
To our knowledge, the influence of alcohol use on the
first trimester screening parameters has not previously
been reported. The aim of this study was to determine
whether alcohol abuse has effects on the first trimester
trisomy screening parameters (NTT, PAPP-A and par-
ticularly on free β-hCG) and whether any of these could
be used as a biomarker of alcohol use during early
pregnancy.
Methods
This is a retrospective cohort study of pregnant women
participating in routine combined FTS for trisomy 21 in
the Kuopio University Hospital area in Central Finland.
The pregnancies, recorded during FTS in routine mater-
nal care between June 2010 and June 2011, were
searched from the medical database. The pregnancy and
birth outcomes were evaluated, and 544 study samples
were selected out of all pregnancies during that time in
the Kuopio University Hospital region (approximately
2500 pregnancies in total) (Fig. 1). A risk ratio < 1:250
was considered normal. The mothers having increased
risk ratios (including trisomies, fetal abnormalities, van-
ishing twins) were excluded from the control group to
keep it as “normal” as possible for revealing the possible
effect of alcohol and drug exposure on screening
parameters.
The final study group included 71 alcohol and possibly
drug abusing mothers (“Abusers”), and for comparison
all 88 Smokers (five or more cigarettes per day during
Fig. 1 Flowchart showing the number of included and excluded subjects. The discrepancy in the number of the smokers in different boxes is
explained by the definition of the final Smokers group (≥ 5 cigarettes/day). Control mothers having increased risk ratio were excluded. Every 8th
mother was selected randomly out of all the criteria fulfilling non-smoking mothers to obtain an appropriate number of controls. Thirty-three
(42.3%) out of the 71 Abusers were smoking (≥ 5 cigarettes/day) during the pregnancy
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the pregnancy) having no history of alcohol or drug
abuse and all 168 non-smoking (not alcohol or drug
abusing) mothers having later given birth to an SGA
child (defined here as birth weight below the 10th per-
centile for gestational age and) (“SGA mothers”). These
comparison groups were included, since giving birth to
an SGA baby and smoking are common among alcohol
abusing mothers. We compared the study groups with
217 non-smoking control mothers having later delivered
a normal-sized newborn (birth weight between the 10th
and 90th percentile) (“Controls”). The inclusion criteria
for the Controls were singleton pregnancy, non-
complicated vaginal birth (cephalic presentation), and
normal outcome: the mother or the newborn did not re-
quire pre- or postnatal follow-up, care or interventions
more than considered to be routine. The Controls were
healthy women who did not have any other diagnosis at
the time of the delivery than a spontaneous, normal par-
turition according to ICD-10 criteria. Every 8th mother
was selected randomly out of all the criteria fulfilling
non-smoking mothers to obtain an appropriate number
of controls. All mothers were Caucasians by their ethnic
background.
The alcohol and drug using pregnant women followed
in the maternity clinic of the Kuopio University Hospital
had been referred by general practitioners due to con-
cerns aroused by alcohol or drug abuse. The alcohol Use
Disorder Identification Test (AUDIT) [4, 5] was used to
identify mothers with harmful patterns of alcohol con-
sumption. The AUDIT questionnaire is a validated test
used to determine if a person is at risk for alcohol abuse
problems. The inclusion criteria for the Abusers were a
total AUDIT score of eight or more, alcohol use during
the ongoing pregnancy or any alcohol/drug abuse before
or during the ongoing pregnancy. The previous risk
users were defined as mothers having any previous use
of IV drugs, rehabilitation due to drug abuse or long-
term use of opioids, stimulants or other drug abuse.
Mothers who were Hepatitis C virus antibody positive,
in drug or alcohol substitute treatment or committed
themselves to drug and/or alcohol abstinence, and
mothers who had quit all drug abuse when noting to be
pregnant were also defined as previous risk users. After
data and outcome collection we did not follow up the
mothers or the children.
FTS was performed according to the recommenda-
tions of the Finnish ministry of Social Affairs and Health
[13]. The screening parameters included PAPP-A and
free β-hCG analyses from maternal serum, and fetal
NTT measurements. Serum samples for PAPP-A and
free β-hCG measurements were collected in maternity
care units between gestational weeks 9 + 0 and 11 + 6.
Blood samples were allowed to clot at room temperature
for 30 min, centrifuged, separated, and stored at + 4 °C.
Serum samples were delivered to the Eastern Finland La-
boratory Centre in Kuopio refrigerated or frozen and
stored at -20 °C. Serum concentrations of free β-hCG
and PAPP-A were analyzed by time-resolved fluoroim-
munoassay according to the manufacturer’s instructions
(PerkinElmer Life and Analytical Sciences, Wallac,
Turku, Finland) and the routine first trimester aneu-
ploidy screening protocol. The intra- and interassay
coefficients of variation (CV) were < 1.8% and < 3.7% for
PAPP-A, and < 2.3% and < 4.1% for free β-hCG,
respectively. The CVs were determined in 20 aliquots of
two serum pools analyzed in either the same or
consecutive runs. The calibrators covered the ranges
10-2000 mU/L for PAPP-A and 2-200 ng/ml for free
β-hCG. Serum samples were diluted 5-fold prior to
the assay of PAPP-A.
The fetal NTT measurements were performed at
healthcare centres or the Kuopio University Hospital
Clinic by ultrasound-trained mid-wives and gynecolo-
gists between the gestational weeks 11 + 0 and 13 + 6.
The crown rump length of the fetus obtained from the
ultrasonography examination determined the gestational
age. The concentrations of the serum markers and the
fetal NTT measures were converted to multiples of me-
dians (MoM). The total trisomy risk for trisomy 21, free
β-hCG MoM, PAPP-A MoM and NTT MoM were
calculated using LifeCycle software version 2.2 (Perki-
nElmer Life and Analytical Sciences). The correction
factors for free β-hCG were maternal weight, diabetes
and smoking status, and for PAPP-A maternal weight
and diabetes status. At the time of the analysis the
smoking correction factor for free β-hCG was 0.82.
This study was approved by the Research Ethics Com-
mittee of Kuopio University Hospital. All study partici-
pants provided an informed written consent.
Statistical analyses
Data management and the statistical analyses were per-
formed using SPSS 19 and 21 (SPSS Inc., Chicago, IL,
USA). The continuous variables were tested with the in-
dependent samples t-test, if normally distributed. The
study groups were compared with the Controls. PAPP-
A, free β-hCG and NT showed normal distribution. The
total trisomy risk showed normal distribution after
log10-transformation. The Chi-square test was used to
analyze dichotomous variables. If there were fewer than
five units in any of the classes, the Fischer´s exact test
was used.
Stepwise multiple linear regression analysis was
applied to explain free β-hCG and PAPP-A variation. P-
value less than 0.05 was considered significant. The
following factors were included in the analyses: con-
firmed maternal alcohol use, smoking, drug abuse, and
giving birth to an SGA baby. In addition, a combination
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of (1) maternal alcohol use and smoking, and (2) mater-
nal alcohol use and giving birth to an SGA baby were in-
cluded in the regression analyses. The results of the
regression analyses were shown as beta coefficients (B)
and standardized coefficients (beta).
Results
The main characteristics of the pregnancies, deliveries
and newborns are depicted in Tables 1 and 2. The mean
AUDIT score among the Abusers was 15.3 (SD 9.0) and
smoking was highly prevalent (42.3%) in this group. The
Abusers and Smokers were slightly younger, and the
SGA mothers older than the Controls. The Smokers
were somewhat heavier than the Controls prior to and
at the beginning of the pregnancy. The SGA mothers
and Abusers were more often nulliparous than the Con-
trols. The SGA mothers were shorter and had more
often arterial hypertension and preeclampsia than the
Controls (Table 1).
Out of the 71 Abusers, 17 (24%) had confirmed use of
alcohol, 25 (35%) used alcohol and/or drugs during the
ongoing pregnancy, and 29 (41%) were previous risk
users fulfilling the inclusion criteria. The mean duration
of pregnancy was close to 280 days in all groups
(Table 1). Altogether 16.9% of the Abusers gave birth to
an SGA infant (Table 2). If alcohol exposure during the
ongoing pregnancy was confirmed, an SGA birth was
even more prevalent (6 out of 17 (35%)). Placental to
birth weight ratio was highest in the Abusers (Table 2).
Serum free β-hCG and PAPP-A level comparisons
among the Controls and the study groups showed two
main findings. Firstly, significantly higher free β-hCG
levels were found in the Abusers in comparison to the
Controls. Secondly, PAPP-A levels were significantly
lower in the SGA mothers and Smokers compared with
Table 1 Maternal and pregnancy characteristics of the study groups
Controls (n = 217) Abusers (n = 71) P Smokers (n = 88) P SGA mothers (n = 168) P
Maternal age (years,mean ± SD) 29.1 ± 4.5 25.6 ± 6.1 < 0.001 27.1 ± 5.8 0.004 30.2 ± 5.3 0.028
Maternal height (cm, mean ± SD) 165.4 ± 5.4 165.2 ± 4.7 0.803 164.1 ± 5.8 0.053 163.4 ± 5.8 0.001
Weight at the beginning of
pregnancy (kg, mean ± SD)
64.2 ± 11.4 66.7 ± 14.0 0.140 70.7 ± 16.2 0.001 66.4 ± 37.5 0.423
BMI prior to pregnancy
(kg/m2, mean ± SD)
22.9 ± 4.0 23.9 ± 4.9 0.150 25.8 ± 5.9 < 0.001 24.5 ± 15.4 0.162
Weight gain during pregnancy
(kg, mean ± SD)
12.8 ± 4.2 14.0 ± 6.3 0.217 13.3 ± 6.9 0.610 11.7 ± 4.4 0.03
Nulliparous, n (%) 60 (27.6) 49 (69.0) < 0.001 29 (33.0) 0.356 97 (57.7) < 0.001
Arterial hypertension, n (%) 16 (7.4) 7 (9.9) 0.376 10 (11.4) 0.175 34 (20.2) < 0.001
Preeclampsia, n (%) 0 (0) 2 (2.8) NA 6 (6.8) NA 11 (6.5) NA
Alcohol use before pregnancy, n (%) 90 (41.5) 38 (53.5) 0.081 41 (46.6) 0.432 76 (45.2) 0.452
Smoking during pregnancy
(≥ 5 cigarrettes/day), n (%)
0 (0) 30 (42.3) NA 88 (100) NA 0 (0) NA
Independent samples t-test was used for continuous variables and Chi-Square test for nominal values. If there were fewer than five units in any of the classes, the
Fischer´s exact test was used. Sample size may vary owing to missing values. NA, not applicable, the parameter was excluded by definition from the
Control group
Table 2 Newborn characteristics in each study group
Controls (n=217) Abusers (n=71) P Smokers (n=88) P SGA mothers (n=168) P
Male gender, n (%) 104 (47.9) 44 (62.0) 0.04 52 (59.1) 0.077 90 (53.6) 0.272
Birth weight (g, mean ±SD) 3540±370 3390±560 0.039 3310±550 0.001 2760±400 <0.001
SGA (birth weight <10 percentile), n (%) 0 (0) 12 (16.9)a NA 16 (18.2) NA 168 (100) NA
Head circumpherence (cm, mean ±SD) 35.2±1.2 34.9±1.8 0.214 35.0±1.9 0.375 33.8±1.8 <0.001
Head circumpherence
(<10th percentile), n (%)
9 (4.1) 14 (19.7) <0.001 10 (11.4) 0.010 45 (26.8) <0.001
Intensive care of the newborn, n (%) 0 (0) 15 (21.1) NA 9 (10.2) NA 13 (7.7) NA
Placental weight (g, mean ±SD) 580±106 610±130 0.048 590±131 0.627 460±79 <0.001
Placental weight/birth weight ratio
(%, mean ±SD)
16.3±2.5 18.1±2.9 <0.001 17.8±3.3 <0.001 16.8±3.0 0.079
Independent samples t-test was used for continuous variables and Chi-Square test for nominal values. If there were fewer than five units in any of the classes, the
Fischer´s exact test was used. Sample size may vary owing to missing values. NA, not applicable, the parameter was excluded by definition from the Control
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the Controls. Fetal NTT did not differ significantly be-
tween the groups (Table 3).
Stepwise multiple linear regression analyses were per-
formed separately for free β-hCG and PAPP-A levels to
explain their variation. Both of these analyses were ad-
justed for confounding factors (listed in the Methods).
Smoking remained the only explaining independent
contributor (B = 0.313, beta = 0.15, P < 0.001) to high free
β-hCG level [F(1,539) = 13.08, P < 0.001, R2 = 0.024)].
Likewise, smoking (B=-0.21, beta=-0.12, P = 0.005) and
giving birth to an SGA baby (B=-0.17, beta=-0.12, P =
0.007) were the only independent contributors to low
PAPP-A levels [F(2,538) = 6.38, P < 0.05, R2 = 0.023].
Total trisomy risk was higher in the Abusers, Smokers
and SGA mothers compared to the Controls (P = 0.047,
mean difference (MD) of the log10-transformed values
− 0.18, 95% CI (-0.35, -0.01), P = 0.047; MD -0.28, 95%CI
(-0.47, -0.09), P = 0.001; MD -0.22, 95%CI (-0.38, -0.06),
P = 0.007, respectively).
Discussion
In this study, we got two main findings. Firstly, we found
increased free β-hCG levels in the Abusers. Secondly, we
found decreased PAPP-A levels in the Smokers and SGA
mothers. Fetal NTT did not differ between the groups.
Although our results suggested increased first trimes-
ter free β-hCG levels in women using alcohol, there was
a significant overlap in free β-hCG levels between the
alcohol-exposed and unexposed women. Forty-two % of
the Abusers smoked during pregnancy and a multiple
regression analysis revealed that smoking explained at
least partly the increase in free β-hCG levels in the
Abusers. This might be due to a stronger influence of
smoking on free β-hCG levels than the correction factor
in the FTS protocol predicted. Another possible factor
explaining higher free β-hCG levels is that the placental
size may have affected hCG production. The Abusers
had higher placental weights than the Controls, which
could partly explain increased free β-hCG levels. The in-
crease in maternal serum free β-hCG levels in the
Abusers could also be a direct effect caused by alcohol
exposure, since ethanol treatment of trophoblast cells
has been shown to increase hCG production in vitro [14,
15]. However, only a small difference and clear overlap
between the Abusers and Controls, and the multiple re-
gression analysis results indicated that the association of
alcohol abuse with free β-hCG is weak and that free β-
hCG cannot be used as a biomarker for alcohol use.
Fetal growth restriction is a classical feature of fetal al-
cohol syndrome and fetal alcohol effects [16], and the
high percentage of SGA births among the Abusers in
the present study (17%) is in line with literature [17].
Previous reports on the association between maternal
serum free β-hCG levels and fetal growth restriction are
conflicting. Fetal growth restriction has been associated
with both decreased [18, 19] and elevated free β-hCG
[20]. Nevertheless, in the present study, later SGA birth
without alcohol or illicit drug exposure did not associate
with altred free β-hCG levels.
Our findings of decreased PAPP-A levels in Smokers
and SGA mothers are in line with previous studies. Both
smoking and fetal growth restriction have previously
been associated with decreased PAPP-A values, but the
clinical utility of decreased PAPP-A to predict an
increased risk to deliver an SGA baby is limited [10, 21–
24]. However, regardless of the high prevalence of SGA
births and smoking in the Abusers, serum PAPP-A levels
of the Abusers were within the low normal range in this
study.
The limitations of this study warrant explanation. The
retrospective design of this study limits the consistency
of the data, especially in the Abusers, where we rely on
database information of the abused agents. The relatively
small sample size is also a limitation in the study. On
the other hand, the AUDIT questionnaire is excellent in
identifying dependency, risk drinking, alcohol use
disorder or risk drinking [4, 5]. The strengths of the
study include the fact that the used serum samples were
collected during routine first trimester hospital visits
and therefore should represent the variation one would
expect to see in clinical samples.
Conclusions
To our best knowledge, this is the first report on the
association between alcohol use during pregnancy and
increased FTS free β-hCG levels. Decreased PAPP-A
among smokers and SGA mothers was in line with pre-
vious studies. The overlap between the study groups was
remarkable and we conclude that free β-hCG is not ap-
plicable for the use as an alcohol biomarker.
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